Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 Summit Therapeutics (NASDAQ: SMMT) will present three posters on ivonescimab at ELCC 2026 on March 27. Updated Phase III HARMONi data show intracranial PFS of 10.1 months vs 6.5 months in patients with baseline brain metastases (HR 0.53; nominal p=0.0068).HARMONi also showed intracranial PFS benefit in patients without baseline CNS metastases (15.7 vs 11.6 months; HR 0.72; nominal p=0.0172). No new safety signals were identified. HARMONi-2 quality-of-life and comparator data versus pembrolizumab (China) will also be presented.

#SMMT Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

www.stocktitan.net/news/SMMT/multiple-ivone...

I see #Nissan #Sunderland is again at risk thanks to #Brexit. #cars #SMMT #Europe

Challenges Faced by the UK Automotive Production in 2025 and the Path to Recovery The UK automotive sector experienced a significant decline in production in 2025, but innovative strategies aim for recovery and growth in 2026.

Challenges Faced by the UK Automotive Production in 2025 and the Path to Recovery #London #United_Kingdom #SMMT #Vehicle_Manufacturing #UK_Automotive_Production

Challenges Facing UK Automotive Manufacturing and Path to Recovery Ahead The UK automotive industry witnessed a significant decline in 2025, but optimistic signs suggest potential recovery through strategic initiatives and new EV production.

Challenges Facing UK Automotive Manufacturing and Path to Recovery Ahead #London #United_Kingdom #electric_vehicles #SMMT #UK_Automotive

UK Automotive Industry Faces Challenges in Production Amid Recovery Strategies The UK automotive sector experienced a significant decline in vehicle production in 2025. However, a strategic shift is now needed for recovery and growth.

UK Automotive Industry Faces Challenges in Production Amid Recovery Strategies #London #United_Kingdom #SMMT #UK_Automotive #vehicle_production

A Challenging Year for the UK Automobile Industry: Key Strategies for Recovery The UK automobile sector faced significant challenges in 2025, with production drops and the need for effective industrial strategies for recovery.

A Challenging Year for the UK Automobile Industry: Key Strategies for Recovery #London #United_Kingdom #SMMT #UK_Production #automobile_industry

Britain’s EV Shift Sparks a Surprise Green Car Boom - Green car sales in the UK hit a 20-year high in 2025 as EV adoption grows, with nearly 100,000 green cars sold, SMMT data shows.

Britain’s EV Shift Sparks a Surprise Green Car Boom
wiobs.com/britains-ev-...
#UKCars #ElectricVehicles #EVNews #AutoIndustry #SMMT #CarTrends #Sustainability #NetZero

#CRSP #SMMT #8eadd0c4-0688-4cf1-bf7b-d27c645ccf07 #investing #Health #Care

Origin | Interest | Match

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with GSK (LSE/NYSE: GSK) to evaluate ivonescimab, an investigational PD-1/VEGF bispecific antibody, in combination with GSK’s B7-H3 ADC risvutatug rezetecan (GSK’227) across multiple solid tumors including small cell lung cancer.The agreement makes Summit the supplier of ivonescimab while GSK will run day-to-day clinical operations. Each party retains rights to its product and the collaboration is mutually non-exclusive. The planned study aims to assess safety and potential anti-tumor effects and is expected to begin dosing patients in mid-2026.

#GSK #SMMT Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

www.stocktitan.net/news/GSK/summit-therapeu...

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 Summit Therapeutics Inc. today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025.. Planned BLA Submission for Ivonescimab in Q4 2025. Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application in order to seek...

#SMMT Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

www.stocktitan.net/news/SMMT/summit-therape...

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer Summit Therapeutics (NASDAQ: SMMT) announced the launch of the global Phase III HARMONi-GI3 trial evaluating ivonescimab + chemotherapy versus bevacizumab + chemotherapy as first-line treatment for unresectable metastatic microsatellite-stable colorectal cancer (MSS/pMMR CRC).The multiregional study intends to enroll ~600 patients, with progression-free survival as the primary endpoint and U.S. site activations planned before year-end; a conference call is scheduled for Oct 20, 2025, 8:00am ET. Earlier Phase II data presented at ESMO 2024 (AK112-206) reported an ORR 81.8% (95% CI 59.7%–94.8%) and DCR 100% in 22 patients; no treatment-emergent adverse events led to permanent discontinuation of ivonescimab as of the data cutoff.

#SMMT Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

www.stocktitan.net/news/SMMT/summit-therape...

Great to see Nur El-Sobky representing Celtic Dynamics at the SMMT Seminar and Networking Event in Oxford fostering collaboration and knowledge-sharing between the energy and motor industries.

#CelticDynamics #SMMT #Innovation

Pomerantz Law Firm Probes Claims from Summit Therapeutics Investors Amid Stock Drop Pomerantz Law Firm is investigating claims from Summit Therapeutics investors following stock plunges related to clinical trial results.

Pomerantz Law Firm Probes Claims from Summit Therapeutics Investors Amid Stock Drop #USA #New_York #Pomerantz_LLP #SMMT #Summit_Therapeutics

Pomerantz Law Firm Probes Securities Claims for Summit Therapeutics Investors Pomerantz LLP launches an investigation concerning potential securities fraud involving Summit Therapeutics, impacting its investors significantly.

Pomerantz Law Firm Probes Securities Claims for Summit Therapeutics Investors #USA #New_York #Pomerantz_Law_Firm #SMMT #Summit_Therapeutics

More cars from yesterday's #SMMT Drive Live event at Coombe Abbey Hotel, Coventry

Sent to Coventry for the new #SMMT Drive Live event at Coombe Abbey, which included a peek at the new Chinese #Changan brand, plus a drive in the epic Hyundai Ioniq 9

@smmt-ukauto.bsky.social @hyundaiuk.bsky.social @hyundai-uk-pr.bsky.social

📢 Stocks Trending NOW: #HOOD #APP #QS #BIDU #SMMT #OCTO #ASTS #UNH #SATS #PL

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332 Summit Therapeutics (NASDAQ:SMMT) announced updated results from the global Phase III HARMONi trial for ivonescimab, a novel PD-1/VEGF bispecific antibody. The trial demonstrated an improved overall survival (OS) hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.Key findings include statistically significant progression-free survival (PFS) with a hazard ratio of 0.52 (p

#SMMT Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

www.stocktitan.net/news/SMMT/ivonescimab-pl...

Electric van demand bucks the trend, surging despite an overall downturn in the UK's vehicle market. SMMT reports a bright spot in electrification amid broader economic challenges. ElectricVehicles #EVs #Vans #Automotive #UKeconomy #SMMT #ElectricVans Link

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SU, #NEM, #NE, #BSX, #SMMT

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SU 27.1x
2. #NEM 24.4x
3. #NE 16.7x
4. #BSX 14.1x
5. #SMMT 10.0x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SMMT, #BEAM, #LYFT, #HNGE, #QS

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SMMT 10.0x
2. #BEAM 4.2x
3. #HUT 4.1x
4. #GOOG 3.8x
5. #LYFT 3.6x

#OptionFlow #OptionsTrading #Trading

#PFE #^GSPC #VRTX #SMMT #5d451519-d139-49e5-aec0-fec0cb634f45 #investing

Origin | Interest | Match

Zusammenfassung: Der britische Automobilsektor zeigt Dynamik! Die SMMT (Society of Motor Manufacturers and Traders) freut sich über neue Mitglieder im August 2025. Ein Zeichen für Wachstum und Innovation in der Branche. Hashtags: Automobilsektor #UK #SMMT #... Link

Les prix des véhicules utilitaires légers d'occasion continuent d'augmenter en juillet, selon SMMT. Une tendance à la hausse qui persiste, soulignant la forte demande pour ces véhicules. #VUL #occasion #SMMT #automobile #marchéauto #tendance Link

Novel Lung Cancer Drug Achieves Breakthrough Results Where Previous Treatments Failed, Phase 3 Data Shows Summit's ivonescimab demonstrates significant 48% risk reduction in advanced lung cancer patients resistant to standard therapy. Key data to be featured at WCLC 2025. Learn more.

#SMMT Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

www.stocktitan.net/news/SMMT/ivonescimab-da...

2.442 E-Transporter wurden im Juli im Vereinigten Königreich ausgeliefert – ein Plus von 72,6 Prozent. Im bisherigen Jahresverlauf machen E-Fahrzeuge jedoch nur 8,8 Prozent des Transporter-Marktes aus.
www.smmt.co.uk/eight-months... #UK #eTransporter #SMMT

2,442 battery electric vans were registered in the UK in July, 72.6% more than last year. However, so far this year, electric vehicles account for only 8.8 per cent of the van market.

www.smmt.co.uk/eight-months... #UK #July #SMMT

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 Summit Therapeutics (NASDAQ:SMMT) reported significant progress in Q2 2025, highlighted by positive results from multiple Phase III trials of ivonescimab. The HARMONi trial demonstrated statistically significant improvement in progression-free survival with a hazard ratio of 0.52 (p<0.00001) in EGFR-mutated NSCLC patients.The company's financial position showed $297.9 million in cash and investments as of June 30, 2025, down from $412.3 million in December 2024. A significant non-cash expense of $466.6 million was recorded due to stock option modifications. The company established a new $360 million ATM offering facility with J.P. Morgan.Key operational highlights include positive interim survival analysis in the HARMONi-2 study, NMPA approval in China for first-line PD-L1 positive advanced NSCLC, and a new clinical collaboration with Revolution Medicines for RAS(ON) inhibitor combinations.

#SMMT Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

www.stocktitan.net/news/SMMT/summit-therape...